相关实验视频
Updated: Sep 10, 2025

04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
446
在患有双相情感障碍高风险因素的患者中使用和疗效:随机对照试验
Li-Lei Lei1, Chen-Jie Ge2, Hong Wang3
1Department of Neurosis and Psychosomatic Diseases, Huzhou Third Municipal Hospital, The Affiliated Hospital of Huzhou University, Huzhou 313000, Zhejiang Province, China.
World journal of psychiatry
|August 21, 2025
概括
在患有焦虑障碍和双相情感障碍的高风险患者中,氨酸与塞特拉林结合可以更快地缓解焦虑和抑郁. 这种组合疗法改善了治疗结果,并减少了对额外药物的需求.
科学领域:
- 精神病学
- 药理学
背景情况:
- 双极性障碍 (BD) 经常与焦虑症 (AD) 一起发生,使治疗复杂化.
- 奎蒂亚平是一种非典型的抗精神病药物,对BD和AD有效,但其在高风险的AD患者中的使用需要进一步研究.
研究的目的:
- 对患有高风险的阿尔茨海默氏症患者进行联合治疗,以研究奎的疗效和安全性.
- 在这种特定患者群体中,将组合治疗与单一治疗进行比较.
主要方法:
- 一项涉及65名患有AD的高风险BD患者的研究,分为两组:单独治疗塞特拉林 (A组) 和结合治疗塞特拉林加奎 (B组).
- 使用汉密尔顿焦虑量表 (HAMA),汉密尔顿抑郁量表 (HAMD) 和贝赫- 拉斐尔森躁狂量表 (BRMS) 来衡量疗效.
- 在整个治疗期间,对副作用和生理指标进行了监测.
主要成果:
- 与单一治疗相比,组合治疗 (B组) 的HAMA分数在第1周和第24周显著降低.
- 在整个研究中,B组的HAMD得分始终较低,表明抑郁症症状得到了更好的控制.
- 与A组相比,B组的BRMS得分在第8周显著下降,B组的患者需要佐尔皮德的睡眠时间较少.
结论:
- 在患有AD且患有BD风险较高的患者中,将奎与塞特拉林结合治疗,可更快更有效地治疗焦虑和抑郁症状.
- 这种组合治疗改善了整体治疗结果,并可能减少对辅助睡眠药物的需要.
相关概念视频
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Mania and Antimanic Drugs: Overview
319
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
319
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Antidepressant Drugs: MAOIs and Other Agents
344
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
344
Psychosis and Antipsychotic Drugs: Overview
454
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
454
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274

